HC Wainwright Reiterates “Buy” Rating for Immunic (NASDAQ:IMUX)

Immunic (NASDAQ:IMUX)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $8.00 price target on the stock.

Several other research analysts have also recently commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunic in a research report on Monday, December 29th. Roth Mkm started coverage on Immunic in a research note on Friday, November 7th. They set a “buy” rating and a $3.00 price objective on the stock. Chardan Capital raised shares of Immunic to a “strong-buy” rating in a research note on Wednesday, November 19th. Brookline Cap M upgraded shares of Immunic to a “strong-buy” rating in a report on Tuesday, February 3rd. Finally, LADENBURG THALM/SH SH upgraded shares of Immunic to a “strong-buy” rating in a research note on Thursday, October 16th. Four research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $7.40.

Immunic Trading Up 11.3%

Shares of IMUX opened at $0.79 on Monday. The stock has a market capitalization of $95.59 million, a price-to-earnings ratio of -0.96 and a beta of 1.58. Immunic has a 12 month low of $0.51 and a 12 month high of $1.39. The firm has a fifty day simple moving average of $0.63 and a 200 day simple moving average of $0.76.

Immunic (NASDAQ:IMUX) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.05. As a group, research analysts predict that Immunic will post -0.94 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Immunic

Large investors have recently modified their holdings of the stock. Qube Research & Technologies Ltd acquired a new stake in shares of Immunic during the 3rd quarter worth about $29,000. Two Sigma Investments LP acquired a new stake in Immunic during the third quarter worth approximately $52,000. HB Wealth Management LLC acquired a new stake in Immunic during the third quarter worth approximately $81,000. Virtu Financial LLC bought a new stake in shares of Immunic during the third quarter worth approximately $99,000. Finally, GSA Capital Partners LLP acquired a new position in shares of Immunic in the third quarter valued at approximately $170,000. 51.82% of the stock is owned by institutional investors.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.